New Initiative Will Focus on Public Health Preparedness for Emerging, Neglected Diseases
WASHINGTON, D.C. — November 10, 2015 — The Sabin Vaccine Institute (Sabin) today announced that Regina Rabinovich, M.D., M.P.H., has joined its Board of Trustees.
PAHO, DVI and Sabin provide an open forum to discuss the future of dengue
WASHINGTON, D.C. — October 26, 2015 — The Sabin Vaccine Institute (Sabin) today announced that Denise Garrett, MD, MSc, has joined the organization as director of the Coalition against Typhoid (CaT) secretariat.
WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.
WASHINGTON, D.C. – August 11, 2015 – The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) has joined The Onchocerciasis Vaccine for Africa (TOVA) Initiative, which was established this year to develop and test a vaccine for onchocerciasis. Also known as river blindness, onchocerciasis infects an estimated 17 million people, with more than 99 percent of these cases spread throughout 31 countries in sub-Saharan Africa. Approximately 169 million people are at risk of contracting this disease.
LONDON — July 30, 2015 — Sabin Foundation Europe (SFE), the UK partner of the Sabin Vaccine Institute (Sabin), today announced the election of Ms. Cecile Hillary, managing director at Morgan Stanley and co-head of debt capital markets for financial institutions in Europe, to the SFE Board of Trustees.
WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.
WASHINGTON, DC – July 24, 2015 – The Dengue Vaccine Initiative (DVI) a consortium comprised of the International Vaccine Institute, the Johns Hopkins University’s International Vaccine Access Center, Sabin Vaccine Institute and the World Health Organization, is delighted to announce the appointment of Dr. In-Kyu Yoon as its new Director. Dr. Yoon, former Chief of the Department of Virology, Armed Forces Research Institute Medical Sciences in Bangkok, Thailand, will lead DVI starting August, 2015.
WASHINGTON, D.C. — July 13, 2015 — The Sabin Vaccine Institute (Sabin) today released updates on its product development partnership (Sabin PDP) and five Phase 1 clinical trials for two vaccine candidates for human hookworm, one of the most common neglected tropical diseases (NTDs).